Modified APTT Screening for Excluding Factor XIa Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a rapid and simple diagnostic method to exclude the presence of factor XIa inhibitors in patient samples, which are crucial for assessing the risk of bleeding complications during urgent surgical procedures, especially in patients with unknown medical history or medication use.
Innovation Solution
A modified APTT test using factor XI-deficient plasma and neutralizing agents for anticoagulants other than factor XIa inhibitors, followed by calculating the ratio of clotting times in patient and normal plasma samples, allowing exclusion of factor XIa inhibitors based on a predetermined reference value.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional chromogenic assays are used to detect coagulation factor inhibitors, then quantitative determination of therapeutic inhibitors is achieved, but the test complexity and time consumption increase
Solution Approach 1:
The invention extracts and isolates the specific function of detecting factor XIa inhibitors from the complex panel of coagulation tests. By using factor XI-deficient plasma as a selective substrate, the method isolates the detection of factor XIa inhibitor activity from other coagulation factors, enabling a focused assay that reduces overall test complexity while maintaining precision for the specific inhibitor type
Solution Approach 2:
The diagnostic approach is segmented into two distinct parts: a screening phase using the simplified APTT-based method with factor XI-deficient plasma to quickly identify presence/absence of factor XIa inhibitors, and a quantitative phase using chromogenic assays only when needed. This segmentation allows most patients to be assessed with the simpler method, reducing overall complexity while preserving measurement precision for those requiring detailed quantification
2Reliability
If comprehensive coagulation screening is performed on all patients, then accurate coagulation status assessment is achieved, but the time required for urgent surgical procedures increases
Solution Approach 1:
The method performs preliminary action by pre-preparing factor XI-deficient plasma and establishing reference ranges before urgent surgical procedures. The screening assay itself is designed to be rapidly executable, providing preliminary information about factor XIa inhibitor presence that guides subsequent decision-making about whether more time-consuming quantitative assays are necessary, thus reducing overall preparation time while maintaining assessment accuracy
Solution Approach 2:
The invention applies local quality by tailoring the depth of investigation to the specific clinical need. For urgent surgical cases with unknown medication history, the rapid screening provides sufficient local information to make immediate surgical safety decisions. Only if the screening indicates positive results or if clinical circumstances warrant further investigation does the process extend to comprehensive quantitative analysis, optimizing the balance between speed and accuracy for each patient scenario
3Measurement precision
If factor XI-deficient plasma is used in the APTT test, then specificity for detecting factor XIa inhibitors is improved, but the test procedure complexity increases
Solution Approach 1:
Factor XI-deficient plasma serves as an intermediary substrate that specifically mediates the detection of factor XIa inhibitor activity. By using plasma lacking factor XI, the assay creates a controlled environment where any observed inhibition of coagulation activation must be due to factor XIa inhibitors present in the patient sample, not variations in other coagulation factors. This intermediary approach enhances specificity while the use of standard APTT reagents and equipment keeps procedural complexity manageable
Solution Approach 2:
The factor XI-deficient plasma reagent serves multiple functions: it acts as a substrate for coagulation activation, provides a controlled background for inhibitor detection, and enables both qualitative screening and quantitative assessment of factor XIa inhibitors. This multi-functionality reduces the need for multiple specialized reagents and procedures, thereby limiting the increase in test procedure complexity while maintaining high specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides high sensitivity and specificity for detecting the absence of factor XIa inhibitors, enabling accurate assessment of coagulation status and reducing the risk of bleeding complications.
Implementation Method 1
mixed with i) factor XI deficient plasma, and ii) at least one neutralizing substance that neutralizes an anticoagulant other than a factor XIa inhibitor
Implementation Method 2
an intrinsic coagulation activator; b) Measure the clotting time in the first reaction mixture
Data Source
Figure 1
AI summary
The present invention lies in the field of coagulation diagnostics and relates to a method for excluding anticoagulants from the group of factor XIa inhibitors in a patient sample.